Galectin Therapeutics Inc.
GALT
$4.05
-$0.09-2.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.59% | 9.67% | -1.14% | -3.30% | -4.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.07% | -60.02% | -52.67% | -26.33% | -14.24% |
| Operating Income | 54.07% | 60.02% | 52.67% | 26.33% | 14.24% |
| Income Before Tax | 30.98% | 41.91% | 34.46% | 17.25% | 8.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.98% | 41.91% | 34.46% | 17.25% | 8.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.98% | 41.91% | 34.46% | 17.25% | 8.91% |
| EBIT | 54.07% | 60.02% | 52.67% | 26.33% | 14.24% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 33.14% | 43.29% | 35.90% | 18.81% | 17.81% |
| Normalized Basic EPS | 33.38% | 43.53% | 35.98% | 18.85% | 10.93% |
| EPS Diluted | 33.14% | 43.29% | 35.90% | 18.81% | 17.81% |
| Normalized Diluted EPS | 33.38% | 43.53% | 35.98% | 18.85% | 10.93% |
| Average Basic Shares Outstanding | 3.55% | 3.08% | 2.55% | 2.11% | 2.40% |
| Average Diluted Shares Outstanding | 3.55% | 3.08% | 2.55% | 2.11% | 2.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |